Chief Financial Officer · Adverum Biotechnologies, Inc. (ADVM)

Linda Rubinstein

A named executive officer of Adverum Biotechnologies in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,605,925

Salary $499,600Stock awards $0

FY2023: $2,301,333

3rd of 5 named executive officers at Adverum Biotechnologies by FY2024 total.

5 named officers on file for Adverum Biotechnologies, FY2024

Linda Rubinstein’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • ADVM’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adverum Biotechnologies’s whole pay program stands against its peers

  • Adverum Biotechnologies’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADVM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A).

Free

Get Linda Rubinstein’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Linda Rubinstein compensation by year

Adverum Biotechnologies Summary Compensation Table · all 3 fiscal years held
In US dollars, as Adverum Biotechnologies reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$0$198,409$499,600
Bonus$0$0$0
Stock awards$0$0$0
Option awards$0$1,360,340$892,685
Non-equity incentive$0$67,721$199,840
Pension and deferred compensation$0$0$0
All other$111,888$674,863$13,800
Total$111,888$2,301,333$1,605,925

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adverum Biotechnologies, Inc. DEF 14A filed April 28, 2025, accession 0001140361-25-016005, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adverum Biotechnologies, Inc. filed document, accession 0001140361-25-016005. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

$112K
$2.3M
$1.6M
FY22
FY23
FY24
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option62,083—$7.15
Option35,000—$19.90
Option46,042—$21.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Adverum Biotechnologies, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Adverum Biotechnologies’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Laurent FischerPresident and Chief Executive Officer$4,131,290
Kishor SoparkarChief Operating Officer$1,843,178
Linda Rubinstein · this pageChief Financial Officer$1,605,925
Setareh SeyedkazemiChief Development Officer$1,598,442
Rabia OzdenChief Medical Officer$1,305,133

The full Adverum Biotechnologies compensation record

free company brief

This page is one person within Adverum Biotechnologies's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adverum Biotechnologies proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adverum Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Linda Rubinstein's compensation dossier · One-time report. No refunds.